SRSF2 Regulates Alternative Splicing to Drive Hepatocellular Carcinoma Development

Area of Science:

• Molecular Biology
• Oncology
• Genetics

Background:

• Aberrant RNA splicing is implicated in cancer pathogenesis, but its mechanisms are not fully understood.
• The role of splicing factors in hepatocellular carcinoma (HCC) remains largely unexplored.

Purpose of the Study:

• To investigate the role of the splicing factor SRSF2 in hepatocellular carcinoma (HCC).
• To identify SRSF2-regulated alternative splicing events and their contribution to HCC pathogenesis.

Main Methods:

• RNA sequencing (RNA-seq) to identify splicing events.
• Molecular analyses to determine SRSF2 binding and its effect on alternative splicing.
• Assessment of SRSF2 expression and its correlation with patient prognosis in HCC specimens.

Main Results:

• SRSF2 is frequently upregulated in HCC and associated with poor patient prognosis.
• SRSF2 binding regulates alternative exon inclusion/exclusion, leading to cancer-associated splice variants.
• Upregulated SRSF2 promotes HCC cell proliferation and tumorigenic potential by controlling these variants.

Conclusions:

• SRSF2 is a key regulator of RNA splicing dysregulation in HCC.
• SRSF2 acts as an oncogene in HCC by promoting cell proliferation and tumorigenesis.
• SRSF2 holds potential as a prognostic biomarker for hepatocellular carcinoma.